| http://www.w3.org/ns/prov#value | - (LHS), which reported a higher risk of CVD deaths and supraventricular tachycardia in patients receiving ipratropium bromide.3 The LHS also found a dose-effect relationship, with supraventricular tachycardia occurring mostly in patients that were more adherent to their ipratropium bromide treatment, thus supporting the possibility of a causal relationship.
|
